{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:41:56Z","timestamp":1792593716792,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"None"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"DOI":"10.1007\/s40262-026-01721-6","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:06:43Z","timestamp":1792591603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Patient-Centered Approach for Drug\u2013Drug Interaction (DDI) Assessment: Integrating Nested Clinical DDI Studies to Verify Translatability of Healthy Volunteer DDI Data, Minimize Stand-Alone Trials, and Enrich Drug Labeling"],"prefix":"10.1007","author":[{"given":"Cheuk Fung","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Sun","family":"Scaringella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0642-9401","authenticated-orcid":false,"given":"Fenglei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"1721_CR1","unstructured":"EMA. ICH M12 guideline on drug interaction studies: step 5. ICH guidance. Available from: https:\/\/www.ema.europa.eu\/en\/ich-m12-drug-interaction-studies-scientific-guideline#current-version-67814. Accessed 8 Oct 2026."},{"key":"1721_CR2","unstructured":"FDA clinical drug interaction studies: cytochrome P450 enzyme- and transporter-mediated drug interactions. Available from: https:\/\/resource.nlm.nih.gov\/101767646. Accessed 8 Oct 2026."},{"key":"1721_CR3","unstructured":"US FDA. NDA211192 Tibsovo\u00ae multi-discipline review. 2018. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/211192Orig1s000MultidisciplineR.pdf. Accessed 30 Mar 2024."},{"key":"1721_CR4","unstructured":"US FDA. NDA 215341 Kerendia\u00ae integrated review. 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/215341Orig1s000IntegratedR.pdf. Accessed 30 Mar 2024."},{"key":"1721_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/dmd.121.000401","volume":"50","author":"J Yu","year":"2020","unstructured":"Yu J, Wang Y, Ragueneau-Majlessi I. Pharmacokinetic drug\u2013drug interactions with drugs approved by the US Food and Drug Administration in 2020: mechanistic understanding and clinical recommendations. Drug Metab Dispos. 2020;50:1\u20137. https:\/\/doi.org\/10.1124\/dmd.121.000401.","journal-title":"Drug Metab Dispos"},{"key":"1721_CR6","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.clinthera.2022.09.009","volume":"44","author":"J Yu","year":"2022","unstructured":"Yu J, Wang Y, Ragueneau-Majlessi I. Strong pharmacokinetic drug\u2013drug interactions with drugs approved by the US Food and Drug Administration in 2021: mechanisms and clinical implications. Clin Ther. 2022;44:1536\u201344. https:\/\/doi.org\/10.1016\/j.clinthera.2022.09.009.","journal-title":"Clin Ther"},{"key":"1721_CR7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40262-014-0142-5","volume":"53","author":"CTMM de Kanter","year":"2014","unstructured":"de Kanter CTMM, Drenth JPH, Arends JE, Reesink HW, van der Valk M, de Knegt RJ, et al. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2014;53:409\u201327. https:\/\/doi.org\/10.1007\/s40262-014-0142-5.","journal-title":"Clin Pharmacokinet"},{"key":"1721_CR8","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s00228-013-1525-5","volume":"69","author":"PN Morcos","year":"2013","unstructured":"Morcos PN, Moreira SA, Brennan BJ, Blotner S, Shulman NS, Smith PF. Influence of chronic hepatitis C infection on cytochrome P450 3a4 activity using midazolam as an in vivo probe substrate. Eur J Clin Pharmacol. 2013;69:1777\u201384. https:\/\/doi.org\/10.1007\/s00228-013-1525-5.","journal-title":"Eur J Clin Pharmacol"},{"key":"1721_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/coh.0b013e3282f82bf1","volume":"3","author":"L Dickinson","year":"2008","unstructured":"Dickinson L, Khoo S, Back D. Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Curr Opin HIV AIDS. 2008;3:296\u2013305. https:\/\/doi.org\/10.1097\/coh.0b013e3282f82bf1.","journal-title":"Curr Opin HIV AIDS"},{"key":"1721_CR10","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/clpt.2008.302","volume":"85","author":"E Morgan","year":"2009","unstructured":"Morgan E. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 2009;85:434\u20138. https:\/\/doi.org\/10.1038\/clpt.2008.302.","journal-title":"Clin Pharmacol Ther"},{"key":"1721_CR11","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/jcph.1093","volume":"58","author":"DE Coutant","year":"2018","unstructured":"Coutant DE, Hall SD. Disease\u2013drug interactions in inflammatory states via effects on CYP-mediated drug clearance. J Clin Pharmacol. 2018;58:849\u201363. https:\/\/doi.org\/10.1002\/jcph.1093.","journal-title":"J Clin Pharmacol"},{"key":"1721_CR12","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/jcph.418","volume":"55","author":"D Joseph","year":"2015","unstructured":"Joseph D, Rose P, Strelkowa N, Schultz A, Garcia J, Elgadi M, et al. Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers. J Clin Pharmacol. 2015;55:384\u201391. https:\/\/doi.org\/10.1002\/jcph.418.","journal-title":"J Clin Pharmacol"},{"key":"1721_CR13","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1002\/jcph.931","volume":"57","author":"F Huang","year":"2017","unstructured":"Huang F, Marzin K, Koenen R, Kammerer KP, Strelkowa N, Elgadi M, et al. Effect of steady-state faldaprevir on pharmacokinetics of atorvastatin or rosuvastatin in healthy volunteers: a prospective open-label, fixed-sequence crossover study. J Clin Pharmacol. 2017;57:1305\u201314. https:\/\/doi.org\/10.1002\/jcph.931.","journal-title":"J Clin Pharmacol"},{"key":"1721_CR14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/cpt.1998","volume":"109","author":"DA Tatosian","year":"2021","unstructured":"Tatosian DA, Yee KL, Zhang Z, Mostoller K, Paul E, Sutradhar S, et al. A microdose cocktail to evaluate drug interactions in patients with renal impairment. Clin Pharmacol Ther. 2021;109:403\u201315. https:\/\/doi.org\/10.1002\/cpt.1998.","journal-title":"Clin Pharmacol Ther"},{"key":"1721_CR15","unstructured":"Terrier J. Management of metabolic and transporter-related DDI in clinic: implementing PBPK in clinical setting as the first step towards personalised dosing. Presented at the 2025 Marbach DDI Workshop; 1\u20133 June, 2025; Marbach Castle, Germany."},{"key":"1721_CR16","unstructured":"Taskar, K. Disease population vs healthy volunteers: understanding practicalities during drug\u00a0development vs clinical landscape of DDIs. Presented at the 2025 Marbach DDI Workshop; 1\u20133 June, 2025; Marbach Castle, Germany."},{"key":"1721_CR17","unstructured":"US FDA. NDA204042 canagliflozin clinical pharmacology and biopharmaceutics review(s). 2012. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204042Orig1s000ClinPharmR.pdf. Accessed 30 Mar 2024."},{"key":"1721_CR18","unstructured":"US FDA. NDA204629 Jardiance clinical pharmacology and biopharmaceutics review(s). 2014. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/204629Orig1s000ClinPharmR.pdf. Accessed 30 Mar 2024."},{"key":"1721_CR19","unstructured":"US FDA. NDA202293 dapagliflozin clinical pharmacology and biopharmaceutics review(s). 2013. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/202293Orig1s000ClinPharmR.Pdf. Accessed 30 Mar 2024."},{"key":"1721_CR20","unstructured":"US FDA. NDA 213716 voclosporin multi-discipline review. 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/213716Orig1s000MultidisciplineR.pdf. Accessed 30 Mar 2024."},{"key":"1721_CR21","unstructured":"US FDA. Lupkynis\u00ae (voclosporin): prescribing information. 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/213716s000lbl.pdf. Accessed 30 Mar 2024."},{"key":"1721_CR22","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/bcp.12309","volume":"77","author":"SY Ling","year":"2014","unstructured":"Ling SY, Huizinga RB, Mayo PR, Larouche R, Freitag DG, Aspeslet LJ, et al. Cytochrome P450 3A and P-glycoprotein drug\u2013drug Interactions with voclosporin. Br J Clin Pharmacol. 2014;77:1039\u201350. https:\/\/doi.org\/10.1111\/bcp.12309.","journal-title":"Br J Clin Pharmacol"},{"key":"1721_CR23","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1111\/cts.12808","volume":"13","author":"RN Cestari","year":"2020","unstructured":"Cestari RN, de Oliveira RDR, de Souza FFL, Pippa LF, Nardotto GHB, Rocha A, et al. Systemic lupus erythematosus activity affects the sinusoidal uptake transporter OATP1B1 evaluated by the pharmacokinetics of atorvastatin. Clin Transl Sci. 2020;13:1227\u201335. https:\/\/doi.org\/10.1111\/cts.12808.","journal-title":"Clin Transl Sci"},{"key":"1721_CR24","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/cpt.3737","volume":"118","author":"DRJ Kuypers","year":"2025","unstructured":"Kuypers DRJ. Current use of physiologically\u2010based pharmacokinetic (PBPK) modeling in new medicinal product approvals at EMA: a clinical appraisal of voclosporin in lupus nephritis. Clin Pharmacol Ther. 2025;118:542\u20133. https:\/\/doi.org\/10.1002\/cpt.3737.","journal-title":"Clin Pharmacol Ther"},{"key":"1721_CR25","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/cpt.3525","volume":"117","author":"P Paul","year":"2025","unstructured":"Paul P, Colin PJ, Tshinanu FM, Versantvoort C, Manolis E, Blake K. Current use of physiologically based pharmacokinetic modeling in new medicinal product approvals at EMA. Clin Pharmacol Ther. 2025;117:808\u201317. https:\/\/doi.org\/10.1002\/cpt.3525.","journal-title":"Clin Pharmacol Ther"},{"key":"1721_CR26","unstructured":"European Medicines Agency.\u00a0Lupkynis EPAR. 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lupkynis-epar-product-information_en.pdf. Accessed 30 Mar 2024."},{"issue":"1","key":"1721_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/cpt.3625","volume":"118","author":"K Reynolds","year":"2025","unstructured":"Reynolds K, Yang X, Peters SA, Sinha V, Heymann H, Borges LN, et al. ICH M12 drug interaction studies: summary of the efforts to achieve global convergence. Clin Pharmacol Ther. 2025;118(1):33\u201344. https:\/\/doi.org\/10.1002\/cpt.3625.","journal-title":"Clin Pharmacol Ther"},{"key":"1721_CR28","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/qad.0000000000000579","volume":"29","author":"D Dieterich","year":"2015","unstructured":"Dieterich D, Nelson M, Soriano V, Arast\u00e9h K, Guardiola JM, Rockstroh JK, et al. Faldaprevir and pegylated interferon \u03b1-2a\/ribavirin in individuals co-infected with hepatitis C virus ggenotype-1 and HIV. AIDS. 2015;29:571\u201381. https:\/\/doi.org\/10.1097\/qad.0000000000000579.","journal-title":"AIDS"},{"key":"1721_CR29","unstructured":"Rockstroh J, Valantin M-A, Mallolas J, Puoti M, Pineda J, Ingiliz P, et al. Pharmacokinetics of faldaprevir and antiretrovirals in patients with HIV\/HCV co-infection. In: 2014 Conference on Retroviruses and Opportunistic Infections (CROI); 3\u20136 March, 2014; Boston (MA)."},{"key":"1721_CR30","unstructured":"Reminyl\u00ae (galantamine hydrobromide): prescribing information. 2001. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2001\/21169lbl.pdf. Accessed 30 Mar 2024."},{"key":"1721_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2174\/157488410791110805","volume":"5","author":"F Huang","year":"2010","unstructured":"Huang F, Fu Y. A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer\u2019s disease, in healthy subjects and patients. Curr Clin Pharmacol. 2010;5:115\u201324. https:\/\/doi.org\/10.2174\/157488410791110805.","journal-title":"Curr Clin Pharmacol"},{"key":"1721_CR32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2004","unstructured":"Mangoni AA, Jackson SHD. Age\u2010related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6\u201314. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.02007.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1721_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.eplepsyres.2015.03.003","volume":"113","author":"A Stockis","year":"2015","unstructured":"Stockis A, Chanteux H, Rosa M, Rolan P. Brivaracetam and carbamazepine interaction in healthy subjects and in vitro. Epilepsy Res. 2015;113:19\u201327. https:\/\/doi.org\/10.1016\/j.eplepsyres.2015.03.003.","journal-title":"Epilepsy Res"},{"key":"1721_CR34","unstructured":"US FDA. NDA205836, 205837, 205838 Briviact\u00ae Medical Review(s). 2011. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/205836Orig1s000_205837Orig1s000_205838Orig1s000MedR.pdf. Accessed 30 Mar 2024."},{"key":"1721_CR35","unstructured":"Orencia\u00ae (abatacept): prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docslLabel\/2005\/125118lbl.pdf. Accessed 30 Mar 2024."},{"key":"1721_CR36","unstructured":"US FDA. BLA125118\/000 abatacept clinical pharmrReview. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2005\/125118_S0000_BioPharmR.pdf. Published 2005. Accessed 30 Mar 2024."},{"key":"1721_CR37","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.drudis.2009.05.014","volume":"14","author":"H Zhou","year":"2009","unstructured":"Zhou H, Davis HM. Risk-based strategy for the assessment of pharmacokinetic drug\u2013drug interactions for therapeutic monoclonala antibodies. Drug Discov Today. 2009;14:891\u20138. https:\/\/doi.org\/10.1016\/j.drudis.2009.05.014.","journal-title":"Drug Discov Today"},{"key":"1721_CR38","unstructured":"Stelara\u00ae (ustekinumab): prescribing information. 2009. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761044lbl.pdf. Accessed 30 Mar 2024."},{"key":"1721_CR39","unstructured":"Tivicay\u00ae (dolutegravir): prescribing information. 2013. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/204790lbl.pdf. Accessed 30 Mar 2024."},{"key":"1721_CR40","unstructured":"US FDA. NDA204790 Tivicay\u00ae clinical pharmacology and biopharmaceutics review(s). 2013. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204790Orig1s000ClinPharmR.pdf. Accessed 30 Mar 2024."},{"key":"1721_CR41","unstructured":"Jesduvroq (daprodustat): prescribing information. 2023 Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216951s000lbl.pdf. Accessed 30 Mar 2024."},{"key":"1721_CR42","unstructured":"US FDA. NDA216951 Jesduvroq integrated review. 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/216951Orig1s000IntegratedR.pdf. Accessed 30 Mar 2024."},{"key":"1721_CR43","unstructured":"US FDA. NDA216993 Vanflyta\u00ae multi-discipline review. 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/216993Orig1s000MultidisciplineR.pdf. Accessed 30 Mar 2024."},{"key":"1721_CR44","unstructured":"Vanflyta\u00ae (quizartinib): prescribing information. 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216993s000lbl.pdf. Accessed 30 Mar 2024."},{"key":"1721_CR45","unstructured":"Nelson M, Arasteh K, Jain M, Soriano V, Madruga J, Furtado J, et al. Effect of falpaprevir on atazanzvir pharmacokinetics in patients with HIV\/HCV co-infection. In: Presented at the Conference on Retroviruses and Opportunistic Infections; 3\u20136 Mar, 2014; Boston (MA)."},{"key":"1721_CR46","unstructured":"Rockstroh J, Valantin M, Mallolas J, Puoti M, Pineda JA, Ingiliz P, et al. Pharmacokinetics of faldaprevir and antiretrovirals in patients with HIV\/HCV co-infection. In: Presented at the conference on retroviruses and opportunistic infections; 3\u20136 Mar, 2014; Boston (MA)."},{"key":"1721_CR47","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/s1473-3099(15)00485-5","volume":"16","author":"L Platt","year":"2016","unstructured":"Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16:797\u2013808. https:\/\/doi.org\/10.1016\/s1473-3099(15)00485-5.","journal-title":"Lancet Infect Dis"},{"key":"1721_CR48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.xphs.2018.10.033","volume":"108","author":"M Grimstein","year":"2019","unstructured":"Grimstein M, Yang Y, Zhang X, Grillo J, Huang S-M, Zineh I, et al. Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. Food and Drug Administration\u2019s Office of Clinical Pharmacology. J Pharm Sci. 2019;108:21\u20135. https:\/\/doi.org\/10.1016\/j.xphs.2018.10.033.","journal-title":"J Pharm Sci"},{"key":"1721_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106838","volume":"200","author":"Z Sun","year":"2024","unstructured":"Sun Z, Zhao N, Zhao X, Wang Z, Liu Z, Cui Y. Application of physiologically based pharmacokinetic modeling of novel drugs approved by the U.S. Food and Drug Administration. Eur J Pharm Sci. 2024;200:106838. https:\/\/doi.org\/10.1016\/j.ejps.2024.106838.","journal-title":"Eur J Pharm Sci"},{"key":"1721_CR50","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/cpt.2503","volume":"112","author":"N Hariparsad","year":"2022","unstructured":"Hariparsad N, Ramsden D, Taskar K, Bad\u00e9e J, Venkatakrishnan K, Reddy MB, et al. Current practices, gap analysis, and proposed workflows for PBPK modeling of cytochrome P450 induction: an industry perspective. Clin Pharmacol Ther. 2022;112:770\u201381. https:\/\/doi.org\/10.1002\/cpt.2503.","journal-title":"Clin Pharmacol Ther"},{"key":"1721_CR51","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/cpt.3477","volume":"117","author":"MB Reddy","year":"2025","unstructured":"Reddy MB, Cabalu TD, de Zwart L, Ramsden D, Dowty ME, Taskar KS, et al. Building confidence in physiologically based pharmacokinetic modeling of CYP3A induction mediated by rifampin: an industry perspective. Clin Pharmacol Ther. 2025;117:403\u201320. https:\/\/doi.org\/10.1002\/cpt.3477.","journal-title":"Clin Pharmacol Ther"},{"key":"1721_CR52","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/cpt.1950","volume":"108","author":"TS Samant","year":"2020","unstructured":"Samant TS, Huth F, Umehar K, Schiller H, Dhuria SV, Elmeliegy M, et al. Ribociclib drug\u2013drug interactions: clinical evaluations and physiologically-based pharmacokinetic modeling to guide drug labeling. Clin Pharmacol Ther. 2020;108:575\u201385. https:\/\/doi.org\/10.1002\/cpt.1950.","journal-title":"Clin Pharmacol Ther"},{"key":"1721_CR53","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/ph19030461","volume":"19","author":"Y Ji","year":"2026","unstructured":"Ji Y, Huth F, Wang C, Schiller H, Combes FP, Crown J, et al. Physiologically-based pharmacokinetics of ribociclib drug\u2013drug interactions and organ impairment pharmacokinetics in early breast cancer. Pharmaceuticals. 2026;19:461. https:\/\/doi.org\/10.3390\/ph19030461.","journal-title":"Pharmaceuticals"},{"key":"1721_CR54","unstructured":"US FDA. NDA 217188 Paxlovid clinical pharmacology review(s). 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/217188Orig1s000IntegratedR.pdf. Accessed 30 Mar 2024."},{"key":"1721_CR55","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s11095-022-03274-2","volume":"39","author":"W Lin","year":"2022","unstructured":"Lin W, Chen Y, Unadkat JD, Zhang X, Wu D, Heimbach T. Applications, challenges, and outlook for PBPK modeling and simulation: a regulatory, industrial and academic perspective. Pharm Res. 2022;39:1701\u201331. https:\/\/doi.org\/10.1007\/s11095-022-03274-2.","journal-title":"Pharm Res"},{"key":"1721_CR56","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40262-022-01204-4","volume":"62","author":"JD Gomez-Mantilla","year":"2023","unstructured":"Gomez-Mantilla JD, Huang F, Peters SA. Can mechanistic static models for drug\u2013drug interactions support regulatory filing for study waivers and label recommendations? Clin Pharmacokinet. 2023;62:457\u201380. https:\/\/doi.org\/10.1007\/s40262-022-01204-4.","journal-title":"Clin Pharmacokinet"},{"key":"1721_CR57","unstructured":"US FDA. NDA 210951 apalutamide multi-discipline review. 2018. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210951Orig1s000MultidisciplineR.pdf. Accessed 30 Mar 2024."},{"key":"1721_CR58","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/cpt.1115","volume":"104","author":"R Evers","year":"2018","unstructured":"Evers R, Piquette\u2010Miller M, Polli JW, Russel FGM, Sprowl JA, Tohyama K, et al. Disease\u2010associated changes in drug transporters may impact the pharmacokinetics and\/or toxicity of drugs: a White Paper from the International Transporter Consortium. Clin Pharmacol Ther. 2018;104:900\u201315. https:\/\/doi.org\/10.1002\/cpt.1115.","journal-title":"Clin Pharmacol Ther"},{"key":"1721_CR59","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41573-023-00877-1","volume":"23","author":"A Galetin","year":"2024","unstructured":"Galetin A, Brouwer KLR, Tweedie D, Yoshida K, Sj\u00f6stedt N, Aleksunes L, et al. Membrane transporters in drug development and as determinants of precision medicine. Nat Rev Drug Discov. 2024;23:255\u201380. https:\/\/doi.org\/10.1038\/s41573-023-00877-1.","journal-title":"Nat Rev Drug Discov"},{"key":"1721_CR60","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bcp.15990","volume":"90","author":"S Armani","year":"2024","unstructured":"Armani S, Geier A, Forst T, Merle U, Alpers DH, Lunnon MW. Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: impact on pharmacokinetics and drug\u2013drug interactions. Br J Clin Pharmacol. 2024;90:942\u201358. https:\/\/doi.org\/10.1111\/bcp.15990.","journal-title":"Br J Clin Pharmacol"},{"key":"1721_CR61","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/cpt.807","volume":"103","author":"M Tan","year":"2018","unstructured":"Tan M, Yoshida K, Zhao P, Zhang L, Nolin TD, Piquette\u2010Miller M, et al. Effect of chronic kidney disease on nonrenal elimination pathways: a systematic assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP. Clin Pharmacol Ther. 2018;103:854\u201367. https:\/\/doi.org\/10.1002\/cpt.807.","journal-title":"Clin Pharmacol Ther"},{"key":"1721_CR62","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1517\/17425255.4.8.1065","volume":"4","author":"AW Dreisbach","year":"2008","unstructured":"Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008;4:1065\u201374. https:\/\/doi.org\/10.1517\/17425255.4.8.1065.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1721_CR63","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s40262-022-01173-8","volume":"61","author":"M Gatti","year":"2022","unstructured":"Gatti M, Pea F. The cytokine release syndrome and\/or the proinflammatory cytokines as underlying mechanisms of downregulation of drug metabolism and drug transport: a systematic review of the clinical pharmacokinetics of victim drugs of this drug\u2013disease interaction under different clinical conditions. Clin Pharmacokinet. 2022;61:1519\u201344. https:\/\/doi.org\/10.1007\/s40262-022-01173-8.","journal-title":"Clin Pharmacokinet"},{"key":"1721_CR64","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/s1470-2045(03)01034-9","volume":"4","author":"KA Slaviero","year":"2003","unstructured":"Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol. 2003;4:224\u201332. https:\/\/doi.org\/10.1016\/s1470-2045(03)01034-9.","journal-title":"Lancet Oncol"},{"key":"1721_CR65","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","volume":"18","author":"RW Robey","year":"2018","unstructured":"Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018;18:452\u201364. https:\/\/doi.org\/10.1038\/s41568-018-0005-8.","journal-title":"Nat Rev Cancer"},{"key":"1721_CR66","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/sj.bjc.6600448","volume":"87","author":"LP Rivory","year":"2002","unstructured":"Rivory LP, Slaviero KA, Clarke SJ. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer. 2002;87:277\u201380. https:\/\/doi.org\/10.1038\/sj.bjc.6600448.","journal-title":"Br J Cancer"},{"key":"1721_CR67","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.pharmthera.2006.07.004","volume":"113","author":"SK Kim","year":"2007","unstructured":"Kim SK, Novak RF. The role of intracellular signaling in insulin-mediated regulation of drug metabolizing enzyme gene and protein expression. Pharmacol Ther. 2007;113:88\u2013120. https:\/\/doi.org\/10.1016\/j.pharmthera.2006.07.004.","journal-title":"Pharmacol Ther"},{"key":"1721_CR68","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2165\/11599410-000000000-00000","volume":"51","author":"MJE Brill","year":"2012","unstructured":"Brill MJE, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CAJ. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51:277\u2013304. https:\/\/doi.org\/10.2165\/11599410-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"key":"1721_CR69","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s43440-024-00665-7","volume":"76","author":"K Kosicka-Noworzy\u0144","year":"2024","unstructured":"Kosicka-Noworzy\u0144 K, Romaniuk-Drapa\u0142a A, Sheng Y-H, Yohn C, Brunetti L, Kagan L. Obesity-related drug transporter expression alterations in human liver and kidneys. Pharmacol Rep. 2024;76:1429\u201342. https:\/\/doi.org\/10.1007\/s43440-024-00665-7.","journal-title":"Pharmacol Rep"},{"key":"1721_CR70","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1128\/aac.02278-15","volume":"60","author":"O Kis","year":"2016","unstructured":"Kis O, Sankaran-Walters S, Hoque MT, Walmsley SL, Dandekar S, Bendayan R. HIV-1 alters intestinal expression of drug transporters and metabolic enzymes: implications for antiretroviral drug disposition. Antimicrob Agents Chemother. 2016;60:2771\u201381. https:\/\/doi.org\/10.1128\/aac.02278-15.","journal-title":"Antimicrob Agents Chemother"},{"key":"1721_CR71","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00228-009-0777-6","volume":"66","author":"AE Jones","year":"2010","unstructured":"Jones AE, Brown KC, Werner RE, Gotzkowsky K, Gaedigk A, Blake M, et al. Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur J Clin Pharmacol. 2010;66:475\u201385. https:\/\/doi.org\/10.1007\/s00228-009-0777-6.","journal-title":"Eur J Clin Pharmacol"},{"key":"1721_CR72","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1592\/phco.20.11.898.35262","volume":"20","author":"D Slain","year":"2000","unstructured":"Slain D, Pakyz A, Israel DS, Monroe S, Polk RE. Variability in activity of hepatic CYP3A4 in patients infected with HIV. Pharmacotherapy. 2000;20:898\u2013907. https:\/\/doi.org\/10.1592\/phco.20.11.898.35262.","journal-title":"Pharmacotherapy"},{"key":"1721_CR73","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00228-004-0855-8","volume":"60","author":"J Fellay","year":"2005","unstructured":"Fellay J, Marzolini C, Decosterd L, Golay KP, Baumann P, Buclin T, et al. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacol. 2005;60:865\u201373. https:\/\/doi.org\/10.1007\/s00228-004-0855-8.","journal-title":"Eur J Clin Pharmacol"},{"key":"1721_CR74","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1111\/bcp.14829","volume":"87","author":"LF Pippa","year":"2021","unstructured":"Pippa LF, Vieira CP, Caris JA, Rocha A, Garcia CP, Rezende REF, et al. Clinical treatment for hepatitis C reverses CYP2C19 inhibition. Br J Clin Pharmacol. 2021;87:4013\u20139. https:\/\/doi.org\/10.1111\/bcp.14829.","journal-title":"Br J Clin Pharmacol"},{"key":"1721_CR75","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1016\/j.xphs.2017.04.016","volume":"106","author":"D Reki\u0107","year":"2017","unstructured":"Reki\u0107 D, Reynolds KS, Zhao P, Zhang L, Yoshida K, Sachar M, et al. Clinical drug\u2013drug interaction evaluations to inform drug use and enable drug access. J Pharm Sci. 2017;106:2214\u20138. https:\/\/doi.org\/10.1016\/j.xphs.2017.04.016.","journal-title":"J Pharm Sci"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01721-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01721-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01721-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:06:49Z","timestamp":1792591609000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01721-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":75,"alternative-id":["1721"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01721-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are employees of Boehringer Ingelheim Pharmaceuticals, Inc.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data generated or analyzed during this study are included in this published article (and its supplementary information files).","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not appliable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CFC and YSS: study design, data analysis, literature search, investigation, visualization, reviewing, final approval. FH: conceptualization, study design, supervision, writing, reviewing and editing.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}